Solvonis Therapeutics PLC

Solvonis Therapeutics PLC is a biopharmaceutical company focused on developing small-molecule therapeutics for central nervous system (CNS) disorders, particularly in the areas of addiction and psychiatry. The company has a pipeline that includes two programs for Alcohol Use Disorder (AUD): SVN-001, targeting severe AUD in the UK and EU, and SVN-002, aimed at moderate-to-severe AUD in the U.S. and other markets. Solvonis operates through a model that combines later-stage clinical assets with discovery-stage innovation, primarily in the UK and U.S. markets.

Solvonis Therapeutics PLC is a biopharmaceutical company focused on developing small-molecule therapeutics for central nervous system (CNS) disorders, particularly in the areas of addiction and psychiatry. The company has a pipeline that includes two programs for Alcohol Use Disorder (AUD): SVN-001, targeting severe AUD in the UK and EU, and SVN-002, aimed at moderate-to-severe AUD in the U.S. and other markets. Solvonis operates through a model that combines later-stage clinical assets with discovery-stage innovation, primarily in the UK and U.S. markets.